Home › NCT07226596

Non-Abstinence Outcomes in Methamphetamine Use Disorder

Advancing Non-Abstinence Outcomes in the Treatment of Methamphetamine Use Disorder

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* be age 18 years or older;
* self-report methamphetamine use in the week prior to screening;
* provide a methamphetamine-positive urine sample at screening;
* meet DSM-5 criteria for moderate-severe Methamphetamine Use Disorder (MUD);
* be seeking treatment for their methamphetamine use
* be able and willing to commit to the 12-week intervention, as well as the 12-week post-intervention follow-up
* Individuals who meet these criteria and are stably maintained on buprenorphine or methadone for Opioid Use Disorder (OUD) will also be eligible to participate.

Exclusion Criteria:

* current or past medical or psychiatric illness (e.g., physical dependence on any drug other than buprenorphine requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, severe diagnosis for a SUD other than MUD or treated OUD) that would interfere with study participation in the opinion of the study physicians
* poor venous access precluding blood draws

About the study

Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating the biopsychosocial benefits of reduced methamphetamine use. These data will be used to change current accepted methamphetamine treatment endpoints and accelerate identification of therapies for methamphetamine use disorder.

What is being tested

• Contingency Management (behavioral)

Sponsor: William Stoops · Participants: 300 · Started: Jan 14, 2026

Contact the study team

• William W Stoops, PhD · Phone: 8592575388

Official record on ClinicalTrials.gov — NCT07226596

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.